{
    "id": 3230,
    "fullName": "ESR1 Y537N",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ESR1 (ER alpha) Y537N lies within the ligand-binding domain/AF-2 domain of the Esr1 (Er alpha) protein (PMID: 24185512). Y537N results in activation of the Esr1 (Er alpha) protein and downstream signaling (PMID: 24055055, PMID: 24185510), and results in increased cell proliferation and viability levels as compared to wild-type Esr1 (Er alpha) (PMID: 29533785), and is associated with resistance to endocrine therapies (PMID: 24398047).",
            "references": [
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 1938,
                    "pubMedId": 24055055,
                    "title": "Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24055055"
                },
                {
                    "id": 2335,
                    "pubMedId": 24398047,
                    "title": "Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398047"
                },
                {
                    "id": 1929,
                    "pubMedId": 24185512,
                    "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185512"
                },
                {
                    "id": 1930,
                    "pubMedId": 24185510,
                    "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185510"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "Y537N",
    "createDate": "02/19/2015",
    "updateDate": "07/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 112504,
        "transcript": "NM_000125",
        "gDna": "chr6:g.152098787T>A",
        "cDna": "c.1609T>A",
        "protein": "p.Y537N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-5942 inhibited ESR1 (ER alpha) target gene expression and proliferation of an ESR1 (ER alpha)-positive breast cancer cell line expressing ESR1 Y537N in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 8021,
                "therapyName": "H3B-5942",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3649,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pipendoxifene inhibited cell proliferation of human breast cancer cells expressing ESR1 Y537N, however, exhibited a decreased response when compared to ESR1 wild-type expressing cells in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 3207,
                "therapyName": "pipendoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1853,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ESR1 Y537N were resistant to Nolvadex (tamoxifen) except at the highest dose (PMID: 24398047).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2335,
                    "pubMedId": 24398047,
                    "title": "Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10215,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0810 inhibited growth of breast cancer cells expressing ESR1 Y537N in culture (PMID: 27986707).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ESR1 Y537N were resistant to Falsodex (fulvestrant) (PMID: 24398047).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2335,
                    "pubMedId": 24398047,
                    "title": "Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10226,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU58668 inhibited growth of breast cancer cells expressing ESR1 Y537N in culture (PMID: 27986707).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 5424,
                "therapyName": "RU58668",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bazedoxifene inhibited cell proliferation of human breast cancer cells expressing ESR1 Y537N, however, exhibited a decreased response when compared to ESR1 wild-type expressing cells in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 2737,
                "therapyName": "Bazedoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and H3B-5942 demonstrated synergy in an ESR1 (ER alpha)-positive breast cancer cell line expressing ESR1 Y537N, resulting in decreased proliferation in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 8022,
                "therapyName": "H3B-5942 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10207,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9496 inhibited growth of breast cancer cells expressing ESR1 Y537N in culture, and inhibited tumor growth in xenograft models (PMID: 27986707).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10230,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited ESR1 activity and growth of breast cancer cells expressing ESR1 Y537N in culture, with ESR1 Y537N-expressing cells demonstrating reduced sensitivity compared to cells expressing wild-type ESR1, and inhibited tumor growth in xenograft models (PMID: 27986707).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3643,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited cell proliferation of human breast cancer cells expressing ESR1 Y537N, however, exhibited a decreased response when compared to ESR1 wild-type expressing cells in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 3051,
                "profileName": "ESR1 Y537N"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3660,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 Y537N ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by Faslodex (fulvestrant) in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 14081,
                "profileName": "ESR1 Y537N ESR1 D538G"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3659,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 Y537N ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by pipendoxifene in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 14081,
                "profileName": "ESR1 Y537N ESR1 D538G"
            },
            "therapy": {
                "id": 3207,
                "therapyName": "pipendoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3661,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 Y537N ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by bazedoxifene in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 14081,
                "profileName": "ESR1 Y537N ESR1 D538G"
            },
            "therapy": {
                "id": 2737,
                "therapyName": "Bazedoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3051,
            "profileName": "ESR1 Y537N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14081,
            "profileName": "ESR1 Y537N ESR1 D538G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 112492,
            "transcript": "XM_017010377",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112495,
            "transcript": "XM_011535543",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112493,
            "transcript": "XM_017010376",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112496,
            "transcript": "NM_001122742",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112497,
            "transcript": "XM_017010378",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112498,
            "transcript": "XM_017010379",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112502,
            "transcript": "XM_011535544",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112503,
            "transcript": "NM_001122740",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112499,
            "transcript": "XM_011535545",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112494,
            "transcript": "XM_017010380",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112500,
            "transcript": "NM_001122741",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112501,
            "transcript": "XM_017010381",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 112504,
            "transcript": "NM_000125",
            "gDna": "chr6:g.152098787T>A",
            "cDna": "c.1609T>A",
            "protein": "p.Y537N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}